Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAD106 · 6 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| CAD106 150μg + Adjuvant 1 at middle dose | ACTIVE_COMPARATOR | - |
| CAD106 150μg + Adjuvant 1 at low dose | ACTIVE_COMPARATOR | - |
| Placebo + Adjuvant 1 at middle dose | PLACEBO_COMPARATOR | - |
| CAD106 150μg + Adjuvant 2 at middle dose | ACTIVE_COMPARATOR | - |
| CAD106 150μg + Adjuvant 2 at low dose | ACTIVE_COMPARATOR | - |
| Placebo + Adjuvant 2 at middle dose | PLACEBO_COMPARATOR | - |
| CAD106 450μg + either Adjuvant 1 or 2 at middle dose | ACTIVE_COMPARATOR | - |
| CAD106 450μg + either Adjuvant 1 or 2 at low dose | ACTIVE_COMPARATOR | - |
| Placebo + either Adjuvant 1 or 2 at middle dose | PLACEBO_COMPARATOR | - |
| CAD106 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CAD106 | BIOLOGICAL | 150μg and 450μg doses were reconstituted and administered via intramuscular injection |
| Placebo | BIOLOGICAL | Identical placebo to CAD106 administered via intramuscular injection |
| Alum | BIOLOGICAL | An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106 |
| MF59 | BIOLOGICAL | An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106 |
Inclusion Criteria: * Male and/or female patients below 85 years of age (inclusive) * Diagnosis of mild Alzheimer's Disease * Mini-Mental State Examination (MMSE) 20 to 26 (inclusive) at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 4 weeks prior to c...
Top 20 of 24 competitors
CAD106 is an investigational monoclonal antibody being developed for Alzheimer's disease. It is designed to target the amyloid-beta protein, which is believed to play a role in the disease. CAD106 is currently in Phase 2 clinical trials and is not yet approved by regulatory authorities.
CAD106 targets the amyloid-beta protein, a key component of the plaques found in the brains of Alzheimer's disease patients. By binding to this protein, CAD106 aims to reduce its accumulation and potentially slow the progression of the disease. This mechanism is being studied in clinical trials.
CAD106 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate the safety and efficacy of CAD106 in patients with Alzheimer's disease.
CAD106 is currently in Phase 2 clinical development. It has completed three clinical trials, including one Phase 1 and two Phase 2 studies. These trials have focused on evaluating the safety and tolerability of CAD106 in patients with mild to moderate Alzheimer's disease.
CAD106 has been studied in three completed clinical trials. These include NCT00411580, a Phase 1 safety study in Sweden; NCT00733863, a Phase 2 study in France, Sweden, Switzerland, and the UK; and NCT00795418, a Phase 2 study in the US. A fourth trial, NCT01097096, also Phase 2, was conducted internationally.
CAD106 is a distinct investigational monoclonal antibody targeting amyloid-beta. It is not the same as other approved Alzheimer's drugs, such as cholinesterase inhibitors or NMDA receptor antagonists. CAD106 is still in clinical development and has not been approved for use.